|
US6346614B1
(en)
*
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
|
US6608035B1
(en)
|
1994-10-25 |
2003-08-19 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
US6645943B1
(en)
|
1994-10-25 |
2003-11-11 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
|
EP0882061B1
(en)
|
1996-02-14 |
2004-05-19 |
Isis Pharmaceuticals, Inc. |
Sugar-modified gapped oligonucleotides
|
|
US20030036516A1
(en)
*
|
1997-09-10 |
2003-02-20 |
Sudhir Agrawal |
Method for using oligonucleotides having modified cpg dinucleotides
|
|
AU3465599A
(en)
*
|
1998-04-01 |
1999-10-18 |
Hybridon, Inc. |
Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
|
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
|
US20040063618A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Muthiah Manoharan |
Peptide nucleic acids having improved uptake and tissue distribution
|
|
US20030220486A1
(en)
*
|
1999-04-01 |
2003-11-27 |
Wen-Qiang Zhou |
Mixed backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content
|
|
US7276489B2
(en)
*
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
|
EP1537208A1
(en)
*
|
2002-09-13 |
2005-06-08 |
Replicor, Inc. |
Non-sequence complementary antiviral oligonucleotides
|
|
MXPA05007652A
(es)
*
|
2003-01-16 |
2006-02-22 |
Hybridon Inc |
Modulacion de propiedades inmunoestimulantes de compuestos basados en oligonucleotido mediante la utilizacion de dinucleotidos inmunoestimulantes modificados.
|
|
EP1628531A4
(en)
*
|
2003-05-16 |
2010-06-30 |
Idera Pharmaceuticals Inc |
SYNERGISTIC TREATMENT OF CANCER BY COMMON USE OF IMMUNOMER AND CHEMOTHERAPEUTICS
|
|
WO2005001055A2
(en)
|
2003-06-11 |
2005-01-06 |
Hybridon, Inc. |
Stabilized immunomodulatory oligonucleotides
|
|
WO2005009355A2
(en)
|
2003-07-15 |
2005-02-03 |
Hybridon, Inc. |
Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
|
|
CN101094594B
(zh)
|
2003-12-08 |
2012-08-15 |
海布里顿公司 |
通过基于小寡核苷酸的化合物调节免疫刺激性质
|
|
AU2005216075B2
(en)
*
|
2004-02-20 |
2011-03-10 |
Idera Pharmaceuticals, Inc. |
Potent mucosal immune response induced by modified immunomodulatory oligonucleotides
|
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
|
US7427405B2
(en)
*
|
2004-06-15 |
2008-09-23 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory oligonucleotide multimers
|
|
BRPI0512110A
(pt)
*
|
2004-06-15 |
2007-10-23 |
Idera Pharmaceutical Inc |
multìmeros de oligonucleotìdeos imunoestimulatórios
|
|
US7935811B2
(en)
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
|
US20060166234A1
(en)
|
2004-11-22 |
2006-07-27 |
Barbara Robertson |
Apparatus and system having dry control gene silencing compositions
|
|
US8003619B2
(en)
|
2004-12-09 |
2011-08-23 |
Alnylam Pharmaceuticals, Inc. |
Method of stimulating an immune response and inhibiting expression of a gene using an oligonucleotide
|
|
BRPI0611452A2
(pt)
|
2005-05-05 |
2010-09-08 |
Antisense Pharma Gmbh |
dosagem de oligonucleotìdeos
|
|
AU2006266503B2
(en)
|
2005-07-01 |
2011-12-08 |
Index Pharmaceuticals Ab |
Immunostimulatory method
|
|
PL2179737T3
(pl)
*
|
2005-07-01 |
2014-01-31 |
Index Pharmaceuticals Ab |
Sposób do modulowania wrażliwości na steroidy
|
|
JP2009513629A
(ja)
*
|
2005-10-28 |
2009-04-02 |
インデックス・ファーマシューティカルズ・アクチエボラーグ |
炎症性疾患を予防、処置、および/または緩和する組成物および方法
|
|
US7776834B2
(en)
*
|
2005-11-07 |
2010-08-17 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
|
CA2628306C
(en)
|
2005-11-07 |
2014-06-17 |
Sudhir Agrawal |
Immunostimulatory oligonucleotide-based compounds with glycerol-linked dinucleotides and modified guanosines at cpg and uses thereof
|
|
US7470674B2
(en)
*
|
2005-11-07 |
2008-12-30 |
Idera Pharmaceuticals, Inc. |
Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
|
|
CN101379195B
(zh)
*
|
2005-12-20 |
2012-05-09 |
艾德拉药物股份有限公司 |
含有不同长度回文片段的回文免疫调节性寡核苷酸(imotm)的免疫刺激活性
|
|
MX2008008278A
(es)
*
|
2005-12-20 |
2008-10-01 |
Idera Pharmaceuticals Inc |
Agonistas sinteticos novedosos de receptores tipo toll que contienen modificaciones de dinucleotido cg.
|
|
CA2660232C
(en)
|
2006-08-08 |
2019-05-21 |
Gunther Hartmann |
Structure and use of 5' phosphate oligonucleotides
|
|
WO2008036825A2
(en)
|
2006-09-22 |
2008-03-27 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by rna interference
|
|
EP2338499A1
(en)
|
2006-10-10 |
2011-06-29 |
Gunther Hartmann |
5' triphosphate oligonucleotide induces anti-viral response
|
|
US8916531B2
(en)
|
2007-11-20 |
2014-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
|
WO2009141146A1
(en)
|
2008-05-21 |
2009-11-26 |
Gunther Hartmann |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
JP5805088B2
(ja)
|
2009-08-27 |
2015-11-04 |
イデラ ファーマシューティカルズ インコーポレイテッドIdera Pharmaceuticals, Inc. |
遺伝子発現を阻害する組成物およびその使用
|
|
US20120270930A1
(en)
|
2009-10-29 |
2012-10-25 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Methods and compositions for dysferlin exon-skipping
|
|
WO2011109427A2
(en)
|
2010-03-01 |
2011-09-09 |
Alnylam Pharmaceuticals, Inc. |
Improving the biological activity of sirna through modulation of its thermodynamic profile
|
|
US9920317B2
(en)
|
2010-11-12 |
2018-03-20 |
The General Hospital Corporation |
Polycomb-associated non-coding RNAs
|
|
EP2453017A1
(en)
|
2010-11-12 |
2012-05-16 |
Antisense Pharma GmbH |
Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases
|
|
DK2638163T3
(en)
|
2010-11-12 |
2017-07-24 |
Massachusetts Gen Hospital |
POLYCOMB-ASSOCIATED NON-CODING RNAs
|
|
US8877722B2
(en)
|
2011-03-25 |
2014-11-04 |
Idera Pharmaceuticals, Inc. |
Compositions for inhibiting gene expression and uses thereof
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
DK2756080T3
(da)
|
2011-09-14 |
2019-05-20 |
Translate Bio Ma Inc |
Multimeriske oligonukleotidforbindelser
|
|
WO2013173598A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating atp2a2 expression
|
|
CA2873769A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating hemoglobin gene family expression
|
|
EA201492116A1
(ru)
|
2012-05-16 |
2015-05-29 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии mecp2
|
|
CA2873794A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating smn gene family expression
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
CN104540946A
(zh)
|
2012-05-16 |
2015-04-22 |
Rana医疗有限公司 |
用于调节utrn表达的组合物和方法
|
|
WO2014030066A2
(en)
|
2012-08-22 |
2014-02-27 |
Bernitz Mats Nilsson |
Methods for identifying nucleic acid sequences
|
|
EP2895200B1
(en)
|
2012-09-14 |
2019-11-06 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
EP4029508A1
(en)
|
2014-10-10 |
2022-07-20 |
Idera Pharmaceuticals, Inc. |
Treatment of cancer using tlr9 agonists and checkpoint inhibitors
|
|
US10858650B2
(en)
|
2014-10-30 |
2020-12-08 |
The General Hospital Corporation |
Methods for modulating ATRX-dependent gene repression
|
|
US10758558B2
(en)
|
2015-02-13 |
2020-09-01 |
Translate Bio Ma, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
EP3271460A4
(en)
|
2015-03-17 |
2019-03-13 |
The General Hospital Corporation |
RNA INTERACTOM OF POLYCOMB REPRESSIVE COMPLEX 1 (PRC1)
|
|
BR112018003110A2
(pt)
|
2015-08-21 |
2018-09-25 |
Pfizer |
nanopartículas terapêuticas compreendendo um agente terapêutico e métodos de fabricação e uso dos mesmos
|
|
CN117337168A
(zh)
|
2021-04-01 |
2024-01-02 |
渤健马萨诸塞州股份有限公司 |
向中枢神经系统的核酸递送
|
|
WO2025088117A1
(en)
|
2023-10-25 |
2025-05-01 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Ribonucleic acid construct capable of inducing an immune response, as well as pharmaceutical composition and kit comprising same
|
|
WO2025158069A1
(en)
|
2024-01-25 |
2025-07-31 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
CONSTRUCT COMPRISING mRNA-STRAND AND RETINOIC ACID-INDUCIBLE GENE I (RIG-I)-LIGAND(S), PHARMACEUTICAL COMPOSITION AND KIT COMPRISING THE SAME
|